Eckert & Ziegler has executed with Telix Pharmaceuticals Limited a comprehensive global supply agreement for Eckert & Ziegler’s therapeutic radioisotope Lutetium-177 (non-carrier-added [n.c.a.] 177Lu). The radiopharmaceutical will be used to advance Telix’s portfolio of Molecularly Targeted Radiation (MTR) investigational products.
Eckert & Ziegler will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer). Lutetium-177 is used in precision oncology for targeted radionuclide therapy. The radioisotope Lutetium-177, is linked to tumor specific drugs which then incorporates the radiating element of the radioisotope into the tumor cells, while largely sparing healthy tissue.
"The agreement underlines our outstanding expertise in delivering isotopes to the pharmaceutical industry. With our production facilities in Europe, Asia and in North America, we are excellently positioned to meet the increasing demand for this isotope and related development and manufacturing services," explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert & Ziegler. “Our recently concluded joint venture with Atom Mines LLC provides us with excellent access to the scarce and indispensable precursor ytterbium-176, enabling us to supply lutetium-177 n.c.a. in highest purity and reliably to pharmaceutical customers worldwide.”
Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, “We are pleased to have established this agreement with EZAG, a premier supplier of high-quality medical radioisotopes, who are now part of our global network of lutetium suppliers. We are committed to working with global partners with a reputation for delivering the highest quality isotopes, and a demonstrated commitment to environmentally sustainable production technologies. Telix’s relationship with EZAG is a multi-isotope partnership and we are delighted to include 177Lu access as part of the supply chain.”
Radiotherapeutic agents that are coupled with Lutetium-177 prior to injection are currently under late-stage clinical development for several types of cancer.Back To Top
Eckert & Ziegler, Telix Sign Global Supply Agreement. Appl Rad Oncol.